Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Gains 4%; BSE HEALTHCARE Index Up 0.6%
Mon, 19 Aug 14:40

Glenmark Pharma Gains 4%; BSE HEALTHCARE Index Up 0.6%Image source: hudiemm/www.istockphoto.com

Glenmark Pharma share price has zoomed 4% and is presently trading at Rs 1,628.0.

Meanwhile, the BSE HEALTHCARE index is at 41,394.2 (up 0.6%).

Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 12.5%) and POLY MEDICURE (up 9.2%).

SUVEN PHARMACEUTICALS (down 2.9%) and FORTIS HEALTHCARE (down 1.9%) are among the top losers today.

Over the last one year, Glenmark Pharma has moved up from Rs 797.6 to Rs 1,628.0, registering a gain of Rs 830.4 (up 104.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,819.2 to 41,394.2, registering a gain of 48.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 126.9%), Jubilant Pharmova (up 108.9%) and GSK Pharma (up 106.2%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 80,445.3 .

The top gainers among the BSE Sensex today are Tata Steel (up 2.7%) and TCS (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 24,579.0 (up 0.2%). BPCL and Hindalco are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,401.9 to 80,445.3, registering a gain of 15,043.4 points (up 23.0%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.

For the year ended March 2023, Glenmark Pharma reported 62.0% decrease in net profit to Rs 3,774 million compared to net profit of Rs 9,936 million during FY22. Revenue of the company grew 5.6% to Rs 129,901 million during FY23.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -30.1.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Gains 4%; BSE HEALTHCARE Index Up 0.6%". Click here!